InsuletNASDAQ: PODD

PODD continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign.

To better understand how Insulet (PODD) might perform in the quarter ending September 2024, look beyond Wall Street's basic profit and loss predictions. Instead, focus on the estimates for some of its important metrics. This will give you a clearer picture of the company's potential performance.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with its Omnipod® products, has announced its plans to celebrate National Diabetes Awareness Month and World Diabetes Day through various activities in November. "Individuals living with diabetes face numerous decisions daily to manage their health, which can be very stressful and sometimes hinder their enjoyment of life."

Collaborations will be increased to enhance quick testing in advanced animal models by the fourth quarter of 2024. This effort aims to improve the efficiency of testing processes. The focus will be on developing better methods for these advanced models.

SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a nationwide effort that uses humor to raise awareness about diabetes, challenge negative stereotypes, and promote positive and respectful portrayals of those living with the condition. This campaign aims to educate people about diabetes while also working to lessen the stigma associated with it.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with its Omnipod® products, has announced that it will share its financial results for the third quarter of 2024 on November 7, 2024, after the markets close. On that day, management will also hold a conference call at 4:30 p.m. (Eastern Time). A link to the live call will be provided on the Investor website.

Insulet's Omnipod 5 is expected to boost growth in the next few months. However, the stock is encountering difficulties because of economic uncertainties.

Insulet stock (NASDAQ: PODD) is currently priced at approximately $200 per share, which is about 35% lower than the over $300 it reached in early November 2021. In contrast, its competitor, DexCom stock, has dropped by 55% during the same time frame.

PODD has reached an important achievement with the approval of Omnipod 5 for treating type 2 diabetes.